Monday, 31 August 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

AZERION Stock Was 17.77% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with AZERION (AZRN.AS) rising 17.77% to €2.85 on Wednesday while AEX-Index jumped 0.48% to €771.41.

AZERION's last close was €2.42, 72.18% below its 52-week high of €8.70.

About AZERION

Azerion Group N.V. operates a digital entertainment and media platform worldwide. Its integrated platform offers technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company was founded in 2014 and is headquartered in Schiphol-Rijk, the Netherlands.

Earnings Per Share

As for profitability, AZERION has a trailing twelve months EPS of €-0.09.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -25.21%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19.4%, now sitting on 470.9M for the twelve trailing months.

More news about AZERION (AZRN.AS).

Categories

stockMarket

Tags

Market-Close NowStock PriceClosesStock Market NowEnd of DayAZERIONPrice UpAZRN.ASMarket CloseStock Price UpStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com